Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027242 | 1.00 | DPP4 (0.39) | DPP4DPP7AAK1DPP8DPP9 | |
| SCHEMBL6809878 | 0.87 | DPP4 (0.52) | DPP4DPP7AAK1DPP8DPP9 | |
| SCHEMBL6809881 | 0.87 | DPP4 (0.52) | DPP4DPP7AAK1DPP8DPP9 | |
| SCHEMBL13412181 | 0.87 | DPP4 (0.40) | DPP4DPP7DPP8DPP9TSHR | |
| SCHEMBL8276056 | 0.87 | DPP4 (0.40) | DPP4DPP7DPP8DPP9TSHR | |
| SCHEMBL14003262 | 0.86 | DPP4 (0.40) | DPP4DPP7AAK1DPP8DPP9 | |
| SCHEMBL8296471 | 0.86 | DPP4 (0.40) | DPP4DPP7AAK1DPP8DPP9 | |
| SCHEMBL14272063 | 0.85 | CTSL (0.41) | AAK1KMT2AITGB3ITGA2BMEN1 | |
| SCHEMBL6358510 | 0.85 | DPP4 (0.41) | DPP4DPP7AAK1DPP8DPP9 | |
| SCHEMBL6358508 | 0.85 | DPP4 (0.41) | DPP4DPP7AAK1DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456204-B2 | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070021477-A1 | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
| CN-1809544-A | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO INC (US) | 2006-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021477-A1 | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885AAK1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.